Reviewed by Julian Douwes M.D., Chief Medical Officer, Klinik St. Georg
If you have been told your Lyme test was negative and yet your symptoms persist, you are not alone. Standard Lyme disease testing misses a significant number of cases. Understanding why and knowing what alternatives exist is one of the most important steps in getting an accurate diagnosis.
The problem: Standard two-tier testing (ELISA followed by Western blot) misses an estimated 20–50% of Lyme cases, particularly in chronic or late-stage disease. A negative test does not rule out Lyme.
Why it happens: Standard tests measure antibody response, not the infection itself. Patients with immune dysfunction, early disease, or prior antibiotic treatment may not produce detectable antibodies despite active infection.
What to do about it: Advanced testing methods including EliSpot-LTT, CD57 natural killer cell counts, PCR, and culture testing offer additional diagnostic pathways. Comprehensive panels through specialized laboratories significantly improve diagnostic accuracy.
Lyme disease is often called "the great imitator" because its symptoms overlap with dozens of other conditions: fibromyalgia, chronic fatigue syndrome, multiple sclerosis, depression, rheumatoid arthritis, lupus, and many others. This clinical ambiguity means that diagnosis depends heavily on laboratory testing. And unfortunately, that testing has well-documented limitations.
The core problem is this: most standard Lyme disease tests do not detect the Borrelia bacterium directly. Instead, they detect the immune system's response to the bacterium, specifically the antibodies your body produces in reaction to the infection. This indirect approach introduces multiple points of failure.
Early infection. It takes the immune system weeks to mount a detectable antibody response. During the first 2–4 weeks of infection, when treatment would be most effective, standard tests frequently return negative results because antibodies have not yet reached measurable levels.
Immune suppression. Borrelia is known to modulate the host immune response. In some patients, particularly those with chronic infection, the immune system becomes too suppressed to produce the antibody levels required for a positive test, even though the infection is actively present.
Strain variation. Standard tests were developed based on specific Borrelia strains. Different genospecies (particularly Borrelia afzelii and Borrelia garinii, which are common in Europe) may not trigger the same antibody patterns, leading to false negatives in patients infected with variant strains.
Prior treatment. Patients who received partial antibiotic treatment may have reduced bacterial load sufficient to lower antibody levels below detection thresholds, yet not sufficient to eliminate the infection entirely.
These are not theoretical concerns. They are experienced daily by patients who are told they do not have Lyme disease based on a single test result, when in reality the test simply was not capable of detecting their infection.
The standard diagnostic approach used in most countries follows a two-tier protocol recommended by the CDC (Centers for Disease Control and Prevention) and endorsed by the IDSA (Infectious Diseases Society of America).
The ELISA is a screening test that detects IgM and IgG antibodies to Borrelia burgdorferi in the blood. It is designed to be highly sensitive, meaning it should identify most true infections, with the trade-off of occasionally producing false positives.
How it works: Your blood sample is exposed to Borrelia antigens on a test plate. If antibodies are present, they bind to the antigens and produce a measurable color change. The result is reported as a numerical value compared to a cutoff threshold.
Limitations:
If the ELISA is positive or equivocal, a Western blot is performed as a confirmatory test. This test separates Borrelia proteins by molecular weight and identifies which specific antibody bands are reactive in the patient's blood.
How it works: Borrelia proteins are separated on a gel and transferred to a membrane. The patient's serum is applied, and reactive antibodies bind to specific protein bands. The number and identity of reactive bands determines whether the result is interpreted as positive.
Interpretation criteria:
Limitations:
The two-tier protocol serves an important public health function: it reduces false-positive diagnoses in low-prevalence populations. However, for individual patients with strong clinical suspicion of Lyme disease, the protocol's specificity-focused design comes at the cost of sensitivity, particularly in chronic disease.
Recognizing the limitations of standard serological testing, specialized laboratories have developed additional diagnostic methods that assess different aspects of the immune response or attempt to detect the organism directly.
The EliSpot-LTT is a cellular immunology test that measures T-cell reactivity to Borrelia antigens, rather than circulating antibody levels. This is a fundamentally different approach to diagnosis.
How it works: White blood cells (lymphocytes) are isolated from the patient's blood and exposed to specific Borrelia antigens in the laboratory. If the patient's T-cells have been sensitized by Borrelia infection, they respond by producing cytokines (interferon-gamma or interleukins). Each responding cell produces a visible "spot" that is counted.
Why it matters for chronic Lyme: Because the EliSpot measures cellular immune memory rather than circulating antibodies, it can detect immune recognition of Borrelia in patients whose antibody levels have waned or were never adequately produced. This makes it particularly valuable for patients with chronic infection, previous antibiotic treatment, or immune suppression.
Specialized laboratories such as ArminLabs offer comprehensive Borrelia-specific panels including EliSpot-LTT testing that standard hospital laboratories do not provide. We recommend these panels as part of a thorough diagnostic workup.
CD57+ NK cells are a subset of natural killer cells that become chronically depleted in patients with persistent Lyme disease. While CD57 testing is not diagnostic of Lyme disease per se, it serves as a biomarker for chronic immune suppression associated with Borrelia infection.
How it works: A standard blood draw is analyzed by flow cytometry to count the number of CD57+ natural killer cells. Values below approximately 60 cells/μL are considered low and are associated with chronic Lyme disease in clinical literature.
Clinical utility: CD57 testing is most useful as a monitoring tool during treatment. Rising CD57 counts during therapy correlate with clinical improvement, while persistently low counts may indicate ongoing immune suppression requiring continued treatment. It is not used as a standalone diagnostic test but adds valuable information to the overall clinical picture.
PCR testing detects Borrelia DNA directly in patient samples, making it the most direct diagnostic method available. Unlike serological tests, PCR does not depend on the immune system's ability to produce antibodies.
How it works: DNA is extracted from a patient sample (blood, urine, cerebrospinal fluid, or synovial fluid) and amplified using primers specific to Borrelia DNA sequences. If Borrelia genetic material is present, even in very small quantities, PCR can detect and amplify it.
Strengths: When positive, PCR provides definitive evidence of Borrelia presence. It is not affected by immune suppression, prior treatment, or strain variation (provided appropriate primers are used).
Limitations: Borrelia exists at very low concentrations in the bloodstream. In chronic infection, organisms are often sequestered in tissues rather than circulating in blood. This means PCR sensitivity from blood samples is relatively low (estimated at 10–30%), though sensitivity improves with joint fluid or tissue samples. A negative PCR does not rule out infection.
Culture testing involves attempting to grow Borrelia organisms from patient samples in specialized growth media. A positive culture is considered the gold standard for proving active infection.
Strengths: A positive culture definitively proves the presence of viable Borrelia organisms. It is independent of the immune response and can identify the specific Borrelia species and strain involved.
Limitations: Borrelia is an extremely fastidious organism that grows slowly (generation time of 12–24 hours compared to 20 minutes for common bacteria). Culture sensitivity is low, requiring weeks of incubation, and is available at only a small number of specialized laboratories. It is primarily used in research settings and as a confirmatory test rather than a routine diagnostic tool.
After evaluating numerous laboratories over three decades, we consistently recommend ArminLabs (Augsburg, Germany) as our preferred partner for Borrelia-specific and tick-borne disease diagnostics. Here is why — and what their tests offer that standard laboratories do not.
Standard ELISA tests use antigens derived from actively growing Borrelia. But chronic Lyme patients often harbour persister forms — morphological variants (round bodies, biofilm-embedded forms) that express different surface proteins than the spiral-shaped bacteria standard tests are designed to detect.
ArminLabs' proprietary TickPlex is the first immunoassay to include antigens specifically targeting these persistent forms. This is not a minor technical detail — it addresses one of the fundamental reasons standard testing fails chronic patients.
TickPlex Basic tests for Borrelia (including persister-form antigens). TickPlex Plus expands to simultaneously screen for Ehrlichia, Anaplasma, Bartonella, Babesia, Mycoplasma, Rickettsia, EBV, Coxsackievirus, and Parvovirus B19 — the most common Lyme co-infections and reactivated viruses — from a single blood draw.
Published performance data: approximately 95% sensitivity and 98% specificity, significantly outperforming standard IFT (immunofluorescence) procedures.
Where standard tests measure antibodies (the immune system's downstream products), the EliSpot measures the T-cells themselves — the immune cells that directly recognise Borrelia. This is a fundamentally different and more direct measurement of whether your immune system has encountered the pathogen.
Why this matters for chronic Lyme: Many chronic patients have suppressed antibody production. Their ELISA and Western blot come back negative — not because the infection is absent, but because their immune system has stopped producing detectable antibody levels. The EliSpot bypasses this problem entirely by detecting the cellular immune response, which persists even when antibody production has waned.
ArminLabs' EliSpot can detect a single reactive T-cell in 100,000 — making it between 20 and 200 times more sensitive than standard ELISA. It covers not only Borrelia but also Bartonella, Babesia, Ehrlichia, Anaplasma, Chlamydia, Mycoplasma, Yersinia, Rickettsia, and viral pathogens (EBV, HHV-6, CMV, VZV).
Published sensitivity: approximately 84% with 94% specificity for Borreliosis.
A limitation of standard testing — and even basic EliSpot — is that a positive result tells you the immune system has encountered Borrelia, but not whether the infection is currently active or was resolved in the past.
ArminLabs' iSpot solves this with a dual-cytokine approach. It simultaneously measures two different immune signals:
This distinction is clinically important: it helps your physician determine whether your positive Borrelia result represents an infection that needs treatment now, or one that your immune system has already handled. No standard test provides this level of differentiation.
CD57+ natural killer cells are chronically depleted in patients with persistent Lyme disease. While not diagnostic on its own, the CD57 count serves as a treatment monitoring biomarker — rising counts correlate with clinical improvement, while persistently low counts (below approximately 60 cells/μL) suggest ongoing immune suppression.
We use CD57 testing before, during, and after treatment to objectively track immune recovery alongside symptom improvement.
An underrecognised factor in treatment-resistant Lyme: concurrent mycotoxin exposure. An estimated 60–80% of food crops carry some level of mycotoxin contamination, and patients living or working in mould-affected environments can accumulate toxic burdens that suppress immune function and mimic Lyme symptoms.
ArminLabs' ToxiPlex detects five mycotoxin classes from a single blood sample: Aflatoxin B1, Deoxynivalenol, Fumonisin B1/B2, Ochratoxin A, and Zearalenone. If mycotoxins are contributing to a patient's immune suppression or symptom load, treatment strategy must address this alongside the infection — otherwise antimicrobial therapy works against a compromised immune system.
If you have been bitten by a tick and still have the tick, ArminLabs can test the tick itself via PCR for Borrelia, Babesia, Bartonella, Ehrlichia, Anaplasma, and other tick-borne pathogens. This provides information about potential exposure before the patient's immune system has had time to generate a detectable response — enabling earlier clinical decisions about prophylactic treatment.
Standard hospital laboratories use the two-tier protocol (ELISA + Western blot) because it is recommended by public health guidelines optimised for population-level screening. These tests are designed to minimise false positives in the general population. For individual patients with chronic symptoms and clinical suspicion of Lyme disease, this population-optimised approach sacrifices sensitivity for specificity. Specialised laboratories like ArminLabs are optimised for individual diagnostic accuracy — using multiple complementary methods to close the diagnostic gaps that standard testing leaves open.
No single test can reliably confirm or rule out Lyme disease in all patients. The most accurate diagnostic approach combines multiple methods:
Clinical assessment. A thorough medical history documenting tick exposure, symptom timeline, treatment history, and travel to endemic areas remains the foundation of Lyme diagnosis. An experienced clinician who has evaluated thousands of Lyme patients can identify patterns that laboratory tests alone may miss.
Standard serological testing. ELISA and Western blot provide useful information when positive, particularly in early or acute infection. Positive results support the diagnosis. Negative results should not be used to exclude it in the presence of strong clinical suspicion.
Advanced testing. EliSpot-LTT, CD57, PCR, and other specialized tests add additional diagnostic layers that can detect infection missed by standard serology. The diagnostic laboratory at Klinik St. Georg incorporates these advanced panels as part of the standard evaluation for every patient.
Co-infection screening. Because many patients with Lyme disease carry concurrent tick-borne co-infections (Babesia, Bartonella, Ehrlichia, Anaplasma, Rickettsia), comprehensive diagnostic panels should include testing for these organisms as well. Unidentified co-infections are a common reason for treatment failure.
Immune function assessment. Inflammatory markers (CRP, ESR, cytokine panels), immune cell counts (CD57, natural killer cell activity), and autoantibody screening provide context about the degree of immune dysfunction and help guide treatment planning.
This multilayered approach significantly improves diagnostic accuracy compared to relying on the standard two-tier protocol alone. Our diagnostic team reviews the complete clinical and laboratory picture for every patient, recognizing that Lyme diagnosis is a clinical judgment informed by testing, not a binary result defined by a single assay.
If you have been tested for Lyme disease using standard methods and received negative results, but you continue to experience symptoms consistent with tick-borne illness, consider the following steps:
A negative test is not the same as a negative diagnosis. If your symptoms are real and your clinical picture is consistent with tick-borne infection, you deserve a more thorough evaluation.
In some countries, patients can order certain laboratory panels directly from specialized laboratories. However, we recommend working with a physician who can interpret the results in the context of your full clinical picture. Test results without clinical context can be misleading in both directions.
Standard antibody-based tests (ELISA, Western blot) typically require 2–6 weeks after infection to become positive, because the immune system needs time to produce detectable antibodies. PCR testing can potentially detect Borrelia DNA earlier, but sensitivity from blood samples is limited. An erythema migrans (bull's-eye) rash, if present, is diagnostic on its own and does not require laboratory confirmation to begin treatment.
Yes. Regardless of previous test results, all patients undergo comprehensive diagnostic testing upon arrival at the hospital. This includes advanced Borrelia-specific panels, co-infection screening, immune function markers, and organ function assessments. This ensures that the treatment plan is based on the most current and complete diagnostic picture.
Coverage varies by country and insurance plan. Standard ELISA and Western blot testing is typically covered by health insurance. Advanced testing (EliSpot-LTT, specialized co-infection panels) may not be covered by all insurance plans. Many patients choose to pay for advanced testing out of pocket, considering it a worthwhile investment in diagnostic accuracy.
A comprehensive overview of Lyme borreliosis, from the tick bite to chronic disease, including stages, symptoms, and transmission.
The other tick-borne infections that frequently accompany Lyme disease and complicate both diagnosis and treatment.
How comprehensive diagnostics inform a multimodal treatment program addressing infection, immune dysfunction, and inflammation.
Our medical team reviews your history, previous test results, and symptoms to determine the most appropriate diagnostic approach for your situation.
Request a case review